These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 22946431)

  • 21. [Aerodiol: the efficacy and tolerability of intranasal estrogen administration. An overview].
    Genazzani AR; Cappagli B; Ciaponi M
    Minerva Ginecol; 2003 Jun; 55(3):189-200. PubMed ID: 14581864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic considerations of new insulin formulations and routes of administration.
    Hoffman A; Ziv E
    Clin Pharmacokinet; 1997 Oct; 33(4):285-301. PubMed ID: 9342504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polymer-drug conjugates: recent progress on administration routes.
    Pang X; Yang X; Zhai G
    Expert Opin Drug Deliv; 2014 Jul; 11(7):1075-86. PubMed ID: 24758250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peroral route: an opportunity for protein and peptide drug delivery.
    Sood A; Panchagnula R
    Chem Rev; 2001 Nov; 101(11):3275-303. PubMed ID: 11840987
    [No Abstract]   [Full Text] [Related]  

  • 25. Drug development of intranasally delivered peptides.
    Campbell C; Morimoto BH; Nenciu D; Fox AW
    Ther Deliv; 2012 Apr; 3(4):557-68. PubMed ID: 22834082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Approaches towards enhanced transepithelial drug delivery.
    Majumdar S; Mitra AK
    Discov Med; 2006 Dec; 6(36):229-33. PubMed ID: 17250788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New ways of insulin delivery.
    Heinemann L
    Int J Clin Pract Suppl; 2011 Feb; (170):31-46. PubMed ID: 21323811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peroral delivery systems based on superporous hydrogel polymers: release characteristics for the peptide drugs buserelin, octreotide and insulin.
    Dorkoosh FA; Coos Verhoef J; Ambagts MH; Rafiee-Tehrani M; Borchard G; Junginger HE
    Eur J Pharm Sci; 2002 Jun; 15(5):433-9. PubMed ID: 12036720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging delivery platforms for mucosal administration of biopharmaceuticals: a critical update on nasal, pulmonary and oral routes.
    Thwala LN; Préat V; Csaba NS
    Expert Opin Drug Deliv; 2017 Jan; 14(1):23-36. PubMed ID: 27351299
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel delivery technologies for protein and peptide therapeutics.
    Kumar TR; Soppimath K; Nachaegari SK
    Curr Pharm Biotechnol; 2006 Aug; 7(4):261-76. PubMed ID: 16918403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Controlling the release of proteins/peptides via the pulmonary route.
    Shoyele SA
    Methods Mol Biol; 2008; 437():141-8. PubMed ID: 18369966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Challenges and strategies in developing microneedle patches for transdermal delivery of protein and peptide therapeutics.
    Wu F; Yang S; Yuan W; Jin T
    Curr Pharm Biotechnol; 2012 Jun; 13(7):1292-8. PubMed ID: 22201589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alternative routes of insulin delivery.
    Owens DR; Zinman B; Bolli G
    Diabet Med; 2003 Nov; 20(11):886-98. PubMed ID: 14632713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic delivery of peptides and proteins across absorptive mucosae.
    Sayani AP; Chien YW
    Crit Rev Ther Drug Carrier Syst; 1996; 13(1-2):85-184. PubMed ID: 8853960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delivery of bioactive peptides and proteins across oral (buccal) mucosa.
    Senel S; Kremer M; Nagy K; Squier C
    Curr Pharm Biotechnol; 2001 Jun; 2(2):175-86. PubMed ID: 11480421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-invasive delivery strategies for biologics.
    Anselmo AC; Gokarn Y; Mitragotri S
    Nat Rev Drug Discov; 2019 Jan; 18(1):19-40. PubMed ID: 30498202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Zelrix: a novel transdermal formulation of sumatriptan.
    Pierce M; Marbury T; O'Neill C; Siegel S; Du W; Sebree T
    Headache; 2009 Jun; 49(6):817-25. PubMed ID: 19438727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transcending the skin barrier to deliver peptides and proteins using active technologies.
    Singh N; Kalluri H; Herwadkar A; Badkar A; Banga AK
    Crit Rev Ther Drug Carrier Syst; 2012; 29(4):265-98. PubMed ID: 22746186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent Updates on Novel Approaches in Insulin Drug Delivery: A Review of Challenges and Pharmaceutical Implications.
    Pandey M; Choudhury H; Yi CX; Mun CW; Phing GK; Rou GX; Singh BJKAAJ; Jhee ANA; Chin LK; Kesharwani P; Gorain B; Hussain Z
    Curr Drug Targets; 2018; 19(15):1782-1800. PubMed ID: 29792143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overview of intranasally delivered peptides: key considerations for pharmaceutical development.
    Al Bakri W; Donovan MD; Cueto M; Wu Y; Orekie C; Yang Z
    Expert Opin Drug Deliv; 2018 Oct; 15(10):991-1005. PubMed ID: 30173579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.